marwan g. fakih, md, on combining regorafenib checkpoint inhibition in advanced crc
Published 5 years ago • 51 plays • Length 1:04
Download video MP4
Download video MP3
Similar videos
-
0:48
marwan g. fakih, md, describes the role of kras inhibitors in colorectal cancer
-
1:08
marwan g. fakih, md, on why amg 510 seems promising in colorectal and lung cancers
-
1:05
marwan fakih, md, considers implications from the amg 510 trial
-
1:14
marwan g. fakih, md, on whether kras amplification predicts resistance to egfr therapies
-
1:59
dr. fakih on future directions in crc
-
1:42
marwan g. fakih, md, regarding outcomes from the amg 510 study
-
1:14
dr. fakih on ras mutations in colon cancer
-
0:42
dr. fakih on anti-angiogenesis versus anti-egfr therapy in colon cancer
-
49:34
ercp for hiliary carcinoma
-
8:11
bayer healthcare stivarga® - life in the moments
-
28:45
stomach,ibd, carcinoid tumor, megacolon
-
1:36
optimal dosing of regorafenib in colorectal cancer
-
2:10
axel grothey, md, on the cctg co.26 trial in advanced refractory crc presented at gi 2019
-
1:12
axel grothey, md, on the use of regorafenib in the management of advanced crc
-
1:05
dr. corcoran on the utility of regorafenib in crc
-
1:14
richard kim, md, regarding the use of regorafenib in treatment of colorectal cancer
-
1:35
dr. lockhart on next steps for regorafenib and tas-102 in mcrc
-
1:39
dr. fakih on the use of regional therapy in colorectal cancer
-
1:20
dr. fukuoka on dosage for regorafenib/nivolumab combo in gastric cancer and crc
-
7:35
use of regorafenib in refractory mcrc
-
11:06
utilizing tas102 and regorafenib for future studies
-
5:56
molecular status and subsequent therapies in mcrc
Clip.africa.com - Privacy-policy